Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Clinical Trial FAQs About Us
Search BMS Clinical Trials
BMS Recruiting Study icon

Recruiting

Trial ID CA266-0008  |   NCT07293351

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Summary

  • Phase 1/Phase 2
  • Male and Female Gender icon
  • 18+
    Age Range
  • 53
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with other agents in participants with advanced Renal Cell Carcinoma (RCC)

print Print
email Email

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
  • Participants must have a histologically confirmed diagnosis of locally advanced, unresectable (not amenable to curative surgery or radiation therapy) or metastatic Renal Cell Carcinoma (RCC).
    1. Participants must have clear cell RCC (ccRCC) or non-clear cell RCC (nccRCC) may be enrolled in PartNote: Part 2 may only enroll participants with ccRCC.
      1. Participants may have favorable, intermediate or poor risk disease categories.
        1. Participants must not have received prior systemic therapy for metastatic RCC, with the following exceptions:
          1. One prior adjuvant or neoadjuvant therapy for completely resectable RCC is allowed if such therapy did not include an agent that targets vascular endothelial growth factor (VEGF) or VEGF receptors and if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy.
            1. For Part 1A participants: Prior systemic therapy in the metastatic setting is allowed if the participant has not received any therapy targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) (e.g., ipilimumab).
              1. For Part 1B participants: Prior systemic therapy in the metastatic setting is allowed if the participant has not received prior treatment with cabozantinib.
                1. For Parts 2D and 2E: Prior treatment with a HIF-2α inhibitor or other agent that targets the HIF-2α pathway is not allowed.
                2. Participants must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

                  Exclusion Criteria

                  Exclusion Criteria Icon
                  • Participants must not have any untreated known CNS metastases.
                    1. Participants must not have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of Cycle 1 Day1 (C1D1).
                      1. Participants must not have a history of interstitial lung disease or pneumonitis.
                        1. Participants must not have an uncontrolled pleural or pericardial effusion requiring recurrent therapeutic drainage procedures.
                          1. Participants must not have significant cardiovascular disease, such as myocardial infarction, unstable angina, arterial thrombosis, cerebrovascular accident within 6 months prior to C1D1, uncontrolled hypertension (≥ 150 systolic, ≥ 90 diastolic mm Hg) despite optimal medical management, left ventricular ejection fraction (LVEF) <50% (for Part 2D and 2E) or congenital long QT syndrome.
                            1. Participants must not have a urine protein ≥ 2+ on dipstick or urinalysis at baseline and confirmed proteinuria ≥ 1 g/24 hours or urine protein-creatinine ratio (UPCR) > 1000 mg/g.
                              1. Participants must not have evidence of major coagulation disorders.
                                1. Participants must not have a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolism within 6 months prior to C1D1.
                                  1. Participants must not have a history of abdominal fistula or gastrointestinal (GI) perforation within 6 months.
                                    1. Participants must not have had a major surgery or trauma within 28 days prior to C1D1.
                                      1. For Part 2D and 2E: Receiving ongoing concomitant treatment with sensitive substrates of CYP3A4, CYP2C8, CYP2C9, or CYP2C19 with narrow therapeutic indices within 5 half-lives of the concomitant treatment or up to 28 days, whichever is shorter, prior to randomization.
                                        1. For Part 2D and 2E: Receiving ongoing concomitant treatment with moderate or strong CYP3A4 inducers, or moderate or strong CYP3A4 inhibitors within 5 half-lives of the concomitant treatment, or up to 28 days, whichever is shorter, prior to randomization.
                                          1. For Part 2D and 2E: Has hypoxia defined by a pulse oximeter reading < 92% at rest or requires intermittent or chronic supplemental oxygen.
                                            1. For Part 2D and 2E: Exercise-induced desaturation on a 6-minute walk test, defined as a blood oxygen saturation by pulse oximetry ≤ 88%.
                                              1. For Part 2D and 2E: Presence of significant pulmonary disease/condition (eg, chronic obstructive pulmonary disease, pleural effusion, etc) that, in the opinion of the Investigator, could put participant at increased risk from study intervention or impact interpretation of safety data.
                                                Additional Information *
                                                • Other protocol-defined Inclusion/Exclusion criteria apply.

                                                  Treatment Options

                                                  Study Arms

                                                  ASSIGNED INTERVENTION

                                                  Study Arms

                                                  Experimental: Part 1A: 1A-1 Pumitamig + Ipilimumab

                                                  ASSIGNED INTERVENTION
                                                  • Drug: Pumitamig, Ipilimumab

                                                  Study Arms

                                                  Experimental: Part 1A: 1A-2 Pumitamig + Ipilimumab

                                                  ASSIGNED INTERVENTION
                                                  • Drug: Pumitamig, Ipilimumab

                                                  Study Arms

                                                  Experimental: Part 1B: 1B-1 Pumitamig + Cabozantinib

                                                  ASSIGNED INTERVENTION
                                                  • Drug: Pumitamig, Cabozantinib

                                                  Study Arms

                                                  Experimental: Part 1B: 1B-2 Pumitamig + Cabozantinib

                                                  ASSIGNED INTERVENTION
                                                  • Drug: Pumitamig, Cabozantinib

                                                  Study Arms

                                                  Experimental: Part 2A: 2A-1 Pumitamig + Ipilimumab

                                                  ASSIGNED INTERVENTION
                                                  • Drug: Pumitamig, Ipilimumab

                                                  Study Arms

                                                  Experimental: Part 2A: 2A-2 Pumitamig + Ipilimumab

                                                  ASSIGNED INTERVENTION
                                                  • Drug: Pumitamig, Ipilimumab

                                                  Study Arms

                                                  Experimental: Part 2B: 2B-1 Pumitamig + Cabozantinib

                                                  ASSIGNED INTERVENTION
                                                  • Drug: Pumitamig, Cabozantinib

                                                  Study Arms

                                                  Experimental: Part 2B: 2B-2 Pumitamig + Cabozantinib

                                                  ASSIGNED INTERVENTION
                                                  • Drug: Pumitamig, Cabozantinib

                                                  Study Arms

                                                  Experimental: Part 2C: 2C-1 Pumitamig

                                                  ASSIGNED INTERVENTION
                                                  • Drug: Pumitamig

                                                  Study Arms

                                                  Experimental: Part 2D: 2D-1 Pumitamig + Casdatifan

                                                  ASSIGNED INTERVENTION
                                                  • Drug: Casdatifan, Pumitamig

                                                  Study Arms

                                                  Experimental: Part 2E: 2E-1 Pumitamig + Ipilimumab + Casdatifan

                                                  ASSIGNED INTERVENTION
                                                  • Drug: Casdatifan, Pumitamig, Ipilimumab
                                                  Take the first step to see if you Match to a Clinical Trial – Check Your Eligibility
                                                  Check Your Eligibility
                                                  Answer some questions about Your health to see if you may match to this trial
                                                  Match to a Trial
                                                  If you are a match, click on the study to see the list of study site locations
                                                  Select a Study Site Location
                                                  Select a study site location that is convenient for you
                                                  Register
                                                  Provide your contact details for the study site to connect with you.

                                                  Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you

                                                  Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you